Showing 1601-1610 of 2152 results for "".
- Scientists Unravel the Function of a Sight-Saving Growth Factorhttps://modernod.com/news/scientists-unravel-the-function-of-a-sight-saving-growth-ffactor/2479302/Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye. The peptides might someday be used to treat degenerative retinal diseases, such as age-r
- Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotechhttps://modernod.com/news/arnaud-lacoste-is-named-chief-scientific-officer-of-aurion-biotech/2479293/Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies. Arnaud will lead R&D teams based in Boston and Seattle. “Arnaud is a brilliant scientist, a strategic e
- RETINA-AI Health Awarded US Patent for AI Detection of Eye Diseasehttps://modernod.com/news/retina-ai-health-awarded-us-patent-for-ai-detection-of-eye-disease/2479088/RETINA-AI Health has been awarded a US patent on its artificial intelligence (AI) systems for autonomous detection of eye diseases from images. There are several eye diseases such as diabetic retinopathy, macular degeneration, and glaucoma for which segments of the general population need to be r
- Zeiss Opens New High-Tech Center in San Francisco Bay Areahttps://modernod.com/news/zeiss-opens-new-high-tech-center-in-san-francisco-bay-area/2479038/Zeiss has completed construction of its new R&D, production, sales and customer service site in the San Francisco Bay Area. Bringing together hundreds of Zeiss employees and key functions under one roof, represents a major milestone in the company’s international innovation and growth
- Medicom Healthcare Signs Asset Purchase Agreement of Bimatoprost 0.3 mg/mL, 3mlhttps://modernod.com/news/medicom-healthcare-signs-asset-purchase-agreement-of-bimatoprost-0-3-mg-ml-3ml/2478852/Medicom Healthcare and Famar Health Care Services Madrid have announced the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of Bimatorost 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Under this agreement
- Neurophth Therapeutics Appoints Qiutang Li, PhD, as Chief Scientific Officerhttps://modernod.com/news/neurophth-therapeutics-appoints-qiutang-li-phd-as-chief-scientific-officer/2478800/Wuhan Neurophth Biotechnology, a developer of AAV-delivered gene therapies for the treatment of ocular diseases, announced the appointment of Qiutang Li, PhD, as Chief Scientific Officer. She will be mainly responsible for the company’s global R&D, IND portfolio strategy, and the establ
- AAO: Leading Advocates for Seniors’ Timely Access to Care Legislation Applaud Senate Bill Introductionhttps://modernod.com/news/aao-leading-advocates-for-seniors-timely-access-to-care-legislation-applaud-senate-bill-introduction/2478675/The Regulatory Relief Coalition (RRC), a group of national physician specialty organizations, announced its strong support for the Improving Seniors’ Timely Access to Care Act, legislation introduced today in the U.S. Senate by Senators Sherrod Brown (D-OH) and John Thune (R-SD). The
- Fight for Sight and Prevent Blindness Announce Recipient of the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-recipient-of-the-2020-joanne-angle-public-health-award/2478320/Fight for Sight and Prevent Blindness announced the recipient of the 2020 Joanne Angle Public Health Award as Angela R. Elam, MD, Clinical Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan. The $25,000 grant was awarded for Dr. Elam’s study, “Engag
- Genentech Initiates Phase 3 Trial for Port Delivery System with Ranibizumab in Diabetic Retinopathyhttps://modernod.com/news/late-stage-trial-starts-for-port-delivery-system-with-ranibizumab-in-diabetic-retinopathy/2478224/Genentech has initiated a new phase 3 clinical trial investigating Port Delivery System with ranibizumab (PDS) for people with diabetic retinopathy (DR). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of r
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati